Stronger Sell Today ADMS ranks #2245 as SELL CANDIDATE. Weaker Sell
Today ADMS ranks #2245 as SELL CANDIDATE.

ADMS stock Adamas Pharmaceuticals

ADMS stock
Adamas Pharmaceuticals

March 22, 2019
Change -4.13%
Chart period: 2018-12-24 - 2019-03-22





Will ADMS stock price go up or down on Mon, 25 Mar 2019?

Adamas Pharmaceuticals Forecast and Stock Analysis

Technical ADMS stock analysis for March 22, 2019.

Sell candidate since 2019-03-05 Loss -6.13%
Shorts n/a
Cash n/a
Loans n/a
Beta 1.50
ROA -62.23

Adamas Pharmaceuticals fell by -4.13% in the last day from $7.99 to $7.66 and has now fallen 3 days in a row. The price has been going up and down for this period, and there has been a -1.29% loss for the last 2 weeks. Volume has increased in the last day by 23 179 shares, but on falling prices. This may be an early warning and the risk will be increased slightly for the next couple of days. In total, 293 117 shares bought and sold for approximately $2.25 million.

Close price at the end of the last trading day (Friday, 22nd Mar 2019) of the ADMS stock was $7.66. This is 4.13% less than the trading day before Thursday, 21st Mar 2019.

During day the stock fluctuated 4.31% from a day low at $7.66 to a day high of $7.99.

30 day high of the ADMS stock price was $12.57 and low was $7.43.
90 day high was $12.57 and low was $7.43.
52 week high for the Adamas Pharmaceuticals - $32.90 and low - $7.42.


Adamas Pharmaceuticals is the lower part of a very wide and horizontal trend on short term, and normally this would pose a good buying opportunity, though a break down through the bottom trend line at $7.49 will give a strong sales signal and a trend shift may be expected. Given the current horizontal trend you can expect Adamas Pharmaceuticals with 90% probability to be traded between $7.44 and $12.06 at the end of this period with 90% probability. A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the roof. Stocks turning up in the middle of a horizontal trend are therefore considered to be potential runners.

Click here for today's Top 5 Trending Companies


A buy signal was issued from a pivot bottom point on Wednesday March 13, 2019, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. Adamas Pharmaceuticals holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $7.88 and $9.26. A break-up above any of these levels will issue buy signals. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

RSI14 is 14 and the stock is extremely oversold on RSI14, but some stocks may continue to fall despite the high chance of a correction up. The low RSI lowers the general risk and the stock should be considered if other technical requirements like liquidity and risk-reward are meet.

Access full RSI 14 and RSI 21 lists

Support & Resistance

Adamas Pharmaceuticals finds support from accumulated volume at $7.55.

Support: $7.55 Price: $7.66 Resistance: $7.77


This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.33 between high and low, or 4.31%. For the last week, the stock has had a daily average volatility of 3.49%.

Adamas Pharmaceuticals is overbought on RSI14 (14). Some stocks may go long and hard while being overbought on RSI, but overbought increases the general risk as higher volatility could be expected, and at some level the stock will have a reaction back to gain new strength.

Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.

Overall risk:

Very Low Low Medium High Very High

Evaluation: Sell Candidate

Adamas Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Stronger Sell Today ADMS ranks #2245 as SELL CANDIDATE. Weaker Sell
Today ADMS ranks #2245 as SELL CANDIDATE.